Somaxon Hits Par With IP Suit Over Silenor Generic
Somaxon Pharmaceuticals Inc. slapped Par Pharmaceutical Cos. Inc. with a patent infringement suit Wednesday over Par's bid for regulatory approval to market generic versions of Somaxon's insomnia drug Silenor....To view the full article, register now.
Already a subscriber? Click here to view full article